Narcolepsy drug trial halted early: what happened?
NCT ID NCT06179407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug was safe and could help patients stay awake during the day. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
9 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has a diagnosis of NT1, including a valid polysomnography within the previous 5 years and a current diagnosis of NT1 for at least 6 months based on criteria established by the International Classification of Sleep Disorders- Third Edition, or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) \[American Psychiatric Association 2013\] * Is positive for HLA-DQB1\*06:02 allele supporting a diagnosis of NT1 * Has a baseline history of unequivocal cataplexy prior to initiation of anti-cataplexy medications * Reports a total sleep time of \> 6 hours on at least 4 out of 7 nights each week within the 4 weeks prior to screening visit Exclusion Criteria: * Has history of or current hypertension * Has underlying cardiovascular or cerebrovascular conditions in which an acute rise in blood pressure would pose a clinical concern, including but nor limited to aneurysms or arteriovenous malformations * Has a history of renal or hepatic impairment * Has a history of cardiac ischemia or cerebral ischemia including but not limited to history of stroke, transient ischemic attack, or transient global amnesia * Based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale, is at imminent risk of self-harm or of harm to others in the opinion of the investigator * Mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years * History of cancer (malignancy) * Has a history of any of the following sleep disorders: obstructive sleep apnea (OSA) defined as an Apnea Hypopnea Index \> 15 per hour per the American Academy of Sleep Medicine alternate criteria, primary insomnia (within the past 6 months), circadian rhythm sleep disorder, shift work sleep disorder (within the past 6 months), clinically significant parasomnia at the discretion of the investigator * Has a history of seizure disorder, clinically significant head trauma, or past invasive intracranial surgery or clinically significant dementia * Positive test(s) for Hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Narcolepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bogan Sleep Consultants ( Site 0001)
Columbia, South Carolina, 29201, United States
-
Delta Waves, Inc. ( Site 0008)
Colorado Springs, Colorado, 80918, United States
-
FutureSearch Trials of Neurology ( Site 0004)
Austin, Texas, 78731, United States
-
NeuroTrials Research Inc ( Site 0006)
Atlanta, Georgia, 30328, United States
-
Teradan Clinical Trials, LLC ( Site 0005)
Brandon, Florida, 33511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Awake but asleep: brain waves may explain crushing daytime sleepiness
- Can a new pill tame Narcolepsy's sudden sleep and muscle weakness?
- Can a Low-Sodium sleep drug ease daytime sleepiness in two sleep disorders?
- Do current sleepiness tests work for kids? a new study puts them to the test
- Zapping the Brain's deep centers: a new approach to narcolepsy?
- New test could sharpen diagnosis of narcolepsy and related sleep disorders